OBJECTIVES: In this study, we investigated the potential of umbilical cord blood stem cell lineages to produce C-peptide and insulin. MATERIALS AND METHODS: Lineage negative, CD133+ and CD34+ cells were analyzed by flow cytometry to assess expression of cell division antigens. These lineages were expanded in culture and subjected to an established protocol to differentiate mouse embryonic stem cells (ESCs) toward the pancreatic phenotype. Phase contrast and fluorescence immunocytochemistry were used to characterize differentiation markers with particular emphasis on insulin and C-peptide. RESULTS: All 3 lineages expressed SSEA-4, a marker previously reported to be restricted to the ESC compartment. Phase contrast microscopy showed all three lineages recapitulated the treatment-dependent morphological changes of ESCs as well as the temporally restricted expression of nestin and vimentin during differentiation. After engineering, each isolate contained both C-peptide and insulin, a result also obtained following a much shorter protocol for ESCs. CONCLUSIONS: Since C-peptide can only be derived from de novo synthesis and processing of pre-proinsulin mRNA and protein, we conclude that these results are the first demonstration that human umbilical cord blood-derived stem cells can be engineered to engage in de novo synthesis of insulin.
OBJECTIVES: In this study, we investigated the potential of umbilical cord blood stem cell lineages to produce C-peptide and insulin. MATERIALS AND METHODS: Lineage negative, CD133+ and CD34+ cells were analyzed by flow cytometry to assess expression of cell division antigens. These lineages were expanded in culture and subjected to an established protocol to differentiate mouse embryonic stem cells (ESCs) toward the pancreatic phenotype. Phase contrast and fluorescence immunocytochemistry were used to characterize differentiation markers with particular emphasis on insulin and C-peptide. RESULTS: All 3 lineages expressed SSEA-4, a marker previously reported to be restricted to the ESC compartment. Phase contrast microscopy showed all three lineages recapitulated the treatment-dependent morphological changes of ESCs as well as the temporally restricted expression of nestin and vimentin during differentiation. After engineering, each isolate contained both C-peptide and insulin, a result also obtained following a much shorter protocol for ESCs. CONCLUSIONS: Since C-peptide can only be derived from de novo synthesis and processing of pre-proinsulin mRNA and protein, we conclude that these results are the first demonstration that human umbilical cord blood-derived stem cells can be engineered to engage in de novo synthesis of insulin.
Authors: Mattias Hansson; Anna Tonning; Ulrik Frandsen; Andreas Petri; Jayaraj Rajagopal; Mikael C O Englund; R Scott Heller; Joakim Håkansson; Jan Fleckner; Helen Nilsson Sköld; Douglas Melton; Henrik Semb; Palle Serup Journal: Diabetes Date: 2004-10 Impact factor: 9.461
Authors: G Di Gioacchino; C Di Campli; M A Zocco; A C Piscaglia; M Novi; M Santoro; A Santoliquido; R Flore; P Tondi; P Pola; G Gasbarrini; A Gasbarrini Journal: Transplant Proc Date: 2005 Jul-Aug Impact factor: 1.066
Authors: Christof Stamm; Bernd Westphal; Hans-Dieter Kleine; Michael Petzsch; Christian Kittner; Heiko Klinge; Carl Schümichen; Christoph A Nienaber; Mathias Freund; Gustav Steinhoff Journal: Lancet Date: 2003-01-04 Impact factor: 79.321
Authors: M Howe; J Zhao; Y Bodenburg; C P McGuckin; N Forraz; R G Tilton; R J Urban; L Denner Journal: Cell Prolif Date: 2009-03-25 Impact factor: 6.831
Authors: Christina Basford; Nicolas Forraz; Saba Habibollah; Kendal Hanger; Colin McGuckin Journal: Int J Stem Cells Date: 2010-05 Impact factor: 2.500
Authors: Michael J Haller; Clive H Wasserfall; Kieran M McGrail; Miriam Cintron; Todd M Brusko; John R Wingard; Susan S Kelly; Jonathan J Shuster; Mark A Atkinson; Desmond A Schatz Journal: Diabetes Care Date: 2009-11 Impact factor: 17.152